Markets:

Overview

News

Currencies

International

Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

35.50 -0.73 (-2.01%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.

Via The Motley Fool

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗

February 22, 2026

This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.

Via The Motley Fool

Topics Regulatory Compliance

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗

February 22, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Where Stoke Therapeutics Stands With Analysts ↗

August 13, 2025

Via Benzinga

A Look Ahead: Stoke Therapeutics's Earnings Forecast ↗

August 11, 2025

Via Benzinga

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗

February 22, 2026

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗

February 22, 2026

Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

Top movers in Monday's pre-market session ↗

January 12, 2026

Via Chartmill

The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Experts ↗

January 08, 2025

Via Benzinga

A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics ↗

June 28, 2024

Via Benzinga

Analyst Expectations For Stoke Therapeutics's Future ↗

May 06, 2024

Via Benzinga

Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? ↗

December 10, 2025

This biotech targeting rare genetic diseases reported a notable insider sale following a year of rapid share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗

December 09, 2025

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

6 Analysts Have This To Say About Stoke Therapeutics ↗

November 05, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 04, 2025

Via Benzinga

Examining the Future: Stoke Therapeutics's Earnings Outlook ↗

November 03, 2025

Via Benzinga

What 4 Analyst Ratings Have To Say About Stoke Therapeutics ↗

October 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 22, 2025

Via Benzinga

D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday ↗

July 22, 2025

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

July 18, 2025

Via Benzinga

STOKE THERAPEUTICS INC (NASDAQ:STOK) – A Biotech Stock with Strong Growth Signals ↗

May 29, 2025

STOKE THERAPEUTICS (NASDAQ:STOK) shows strong growth metrics, high profitability improvements, and attractive valuation, making it a candidate for growth investors following Louis Navellier's...

Via Chartmill

Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar ↗

May 01, 2025

The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs.

Via Investor's Business Daily

Topics Earnings

Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics ↗

March 18, 2025

Via Benzinga

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal ↗

February 18, 2025

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 11, 2025

Via Benzinga

Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗

December 04, 2024

Via Benzinga

Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday ↗

June 24, 2024

Via Benzinga

STOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 06, 2024

STOK stock results show that Stoke Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.